ATHIRA PHARMA Trader Recognize: Buyers With Substantial Losses Have Possibility to Lead the Athira Pharma, Inc. Class Motion Lawsuit

SAN DIEGO, July 13, 2021 /PRNewswire/ — The Athira Pharma, Inc. course action lawsuit fees Athira Pharma and its CEO with violations of the Securities Trade Act of 1934 and seeks to represent purchasers of Athira Pharma securities amongst September 18, 2020 and June 17, 2021, inclusive (the “Course Period”). The Athira Pharma class motion lawsuit was commented in the Western District of Washington and is captioned Wang v. Athira Pharma, Inc., No. 21-cv-00861. Two similar lawsuits – Jawandha v. Athira Pharma, Inc., No. 21-cv-00862, and Slyne v. Athira Pharma, Inc., No. 21-cv-00864 – are also pending in the Western District of Washington.

If you endured sizeable losses and want to provide as guide plaintiff of the Athira Pharma course action lawsuit, make sure you present your details by clicking here. You can also contact lawyer J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. Lead plaintiff motions for the Athira Pharma course action lawsuit have to be submitted with the court docket no later on than August 24, 2021.

Scenario ALLEGATIONS: The Athira Pharma class action lawsuit alleges that, throughout the Class Period of time, defendants built wrong and deceptive statements and failed to disclose that: (i) the research done by Athira Pharma’s President and Chief Executive Officer, defendant Leen Kawas, which fashioned the basis for Athira Pharma’s product candidates and mental property, was tainted by Kawas’s scientific misconduct, which include the manipulation of important knowledge and (ii) as a end result, defendants’ positive statements about Athira Pharma’s organization, operations, and prospects were being materially misleading and omitted material points important to make the statements manufactured not deceptive.

On June 17, 2021, Athira Pharma issued a push release saying that Athira Pharma’s Board of Administrators experienced put Kawas on short-term leave pending a overview of actions stemming from doctoral study Kawas carried out while at Washington State University. An post posted in STAT News later on that working day discovered that the investigation of Kawas associated to allegations that she altered images in 4 separate papers relating to her investigation on hepatocyte progress variable (“HGF”), a protein with the possible to take care of Alzheimer’s sickness and other neurological problems. The report famous that even though Athira Pharma “has considering the fact that moved on to a unique molecule than the one particular Kawas was doing the job on, it however aims to target HGF. And so Kawas’s doctoral do the job laid the biological groundwork that Athira proceeds to use in their tactic to dealing with Alzheimer’s.” On this information, Athira Pharma’s stock cost fell by just about 39%, damaging investors.

THE Direct PLAINTIFF Approach: The Non-public Securities Litigation Reform Act of 1995 permits any trader who acquired Athira Pharma securities through the Class Interval to seek out appointment as guide plaintiff in the Athira Pharma class motion lawsuit. A guide plaintiff is normally the movant with the greatest money curiosity in the reduction sought by the putative course who is also standard and satisfactory of the putative class. A lead plaintiff functions on behalf of all other class customers in directing the Athira Pharma class action lawsuit. The direct plaintiff can decide on a regulation organization of its selection to litigate the Athira Pharma class action lawsuit. An investor’s capability to share in any potential long run recovery of the Athira Pharma class motion lawsuit is not dependent on serving as direct plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 attorneys in 9 workplaces nationwide, Robbins Geller Rudman & Dowd LLP is the biggest U.S. regulation firm symbolizing traders in securities course steps. Robbins Geller attorneys have received a lot of of the most significant shareholder recoveries in background, together with the premier securities class motion recovery at any time – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Class Action Companies Top rated 50 Report rated Robbins Geller very first for recovering $1.6 billion for traders past calendar year, a lot more than double the total recovered by any other securities plaintiffs’ agency. Remember to go to https://www.rgrdlaw.com/company.html for much more data.

Legal professional promoting.
Past effects do not warranty upcoming results.
Solutions may possibly be performed by lawyers in any of our places of work.

Get in touch with:
Robbins Geller Rudman & Dowd LLP
655 W. Broadway, San Diego, CA 92101
J.C. Sanchez, 800-449-4900
[email protected]